[Use of rFVIIa (Novoseven) in the case of a patient with mitral valvular prothesis and anticoagulant accident].
We report the case of an haemorrhagic shock observed in a woman who received heparin for a cardiac valve in mitral position, efficiently treated with rFVIIa. The haemorrhagic complications under anticoagulation treatment remain rare, but can lead to real therapeutic dilemma. The use of rFVIIa has been evaluated in different clinical situations, including traumatic or post-operative haemorrhagic shock. The use of rFVIIa in the treatment of haemorrhagic complication under anticoagulation treatment is discussed.
Clapson
P
P
Service d'anesthésie-réanimation, hôpital d'instruction des armées Percy, 101, avenue Henri-Barbusse, BP 406, 92141 Clamart, France. clapson-patrick@wanadoo.fr
Perez
J-P
JP
Debien
B
B
Pasquier
P
P
Lenoir
B
B
Pats
B
B
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006350:Heart Valve Prosthesis; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008943:Mitral Valve; D011994:Recombinant Proteins / Q000627:therapeutic use; D012771:Shock, Hemorrhagic / Q000139:chemically induced* / Q000188:drug therapy*
D000925:Anticoagulants; D011994:Recombinant Proteins; D006493:Heparin; C103587:recombinant FVIIa; D015942:Factor VIIa